CohBar (CohBar) Cash And Cash Equivalents : $6.19 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is CohBar Cash And Cash Equivalents?

CohBar's quarterly cash and cash equivalents declined from Dec. 2022 ($5.93 Mil) to Mar. 2023 ($5.39 Mil) but then increased from Mar. 2023 ($5.39 Mil) to Jun. 2023 ($6.19 Mil).

CohBar's annual cash and cash equivalents increased from Dec. 2020 ($2.90 Mil) to Dec. 2021 ($4.99 Mil) and increased from Dec. 2021 ($4.99 Mil) to Dec. 2022 ($5.93 Mil).

CohBar Cash And Cash Equivalents Historical Data

The historical data trend for CohBar's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Cash And Cash Equivalents Chart

CohBar Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

5.72

12.56

2.90

4.99

5.93

CohBar Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.88	4.21	5.93	5.39	6.19

CohBar Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CohBar (OTCPK:CWBR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CohBar Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CohBar's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CohBar (CohBar) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025

Website

https://www.cohbar.com

CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.

Executives

Stephanie Tozzo	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret	director, officer: Chief Executive Officer	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno	officer: CFO, Treasurer and Secretary	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle	officer: Chief Executive Officer	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood	director	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen	officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern	director, officer: Chief Executive Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025